Eli Lilly is growing faster than any other large drugmaker, driven by strong sales of Mounjaro and new FDA approvals for cardiovascular risk reduction and insulin products. The company plans to seek approval for retatrutide in early 2027, a drug showing promising weight loss results. Despite some pressure from falling U.S. drug prices, analysts remain bullish, raising earnings estimates and setting a price target near $1,400, about 20% above current levels. The stock's premium valuation is supported by its rapid growth compared to peers like Novo Nordisk and Merck. Investors will watch closely for retatrutide's approval and pricing trends to confirm this optimistic outlook.
As of Sep 30, 2026 01:11 WIB, Eli Lilly (LLY) trades at USD 1,183.81, close to its 52-week high of $1.28K, showing a slight 1-day decline of 0.18%. In contrast, Novo Nordisk (NVO) is near its 52-week low at USD 38.17, down 1.39% on the day, while Merck (MRK) holds steady at USD 148.81, just below its 52-week high of $156.43 with a minor 0.07% gain. Eli Lilly's premium valuation and strong buy interest on Pluang, with 76% of orders to buy, highlight its growth appeal compared to peers as investors watch for upcoming drug approvals.
Navitas Semiconductor's shares rose 12% premarket after securing a U.S. Army contract to develop next-generation silicon carbide power semiconductor technology. This project aims to create a domestic manufacturing process for ultra-high-voltage silic...
Eli Lilly's Foundayo (orforglipron) 17.2 mg showed significantly greater weight loss (1.5% more) and A1C reduction (0.3% more) than oral semaglutide 25 mg after 52 weeks in adults with type 2 diabetes, based on an indirect comparison of ACHIEVE-3 and...
Eli Lilly launched the 'Change the Course Commitment' aiming to treat as many diabetes and obesity patients in low- and middle-income countries (LMICs) as in high-income countries by 2040. Currently, only one in four patients in LMICs have access to ...
The FDA approved Eli Lilly's Onswik, a once-weekly basal insulin for adults with type 2 diabetes, marking a useful extension to its diabetes treatments. While the stock rose 2.85% to $1,183.76, this new insulin is unlikely to significantly change the...
The FDA has approved Olumiant (baricitinib), a once-daily pill, for treating severe alopecia areata (AA) in pediatric patients aged 12 and older. This approval is based on positive results from the BRAVE-AA-PEDS Phase 3 study, showing significant sca...
